In January 2025, Gornitzky & Co. merged with life sciences boutique firm Horn & Co, the combination adding expertise in licensing and technology transfers, particularly in the biotech, pharmaceutical and med-tech sectors. Practice head Yuval Horn is a highly-rated expert in licensing, collaboration agreements, technology transfers, clinical trials, and cross-border M&A involving life sciences companies; Shlomo Landress advises on biotech and med-tech sector transactions; and Keren Kanir‘s workload covers transactional and regulatory mandates. The practice further includes Itamar Mei-Zahav, an adviser on licensing deals, university technology transfer agreements, and IP-driven commercial deals.
Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

  • Our experience with the Horn & Co. team, now part of Gornitzky, has been outstanding. The merger brought together Horn’s market-leading strength in high-tech transactions with Gornitzky’s depth, scale, and international reach. For us, this created a seamless transition — we continue to work with the advisors who know our business and the startup ecosystem inside out, while also gaining access to the broader resources needed to support complex, cross-border growth. What sets them apart is their ability to understand the realities of founders, investors, and fast-growing companies. They combine legal precision with a practical, business-minded approach, helping us navigate everything from early-stage financings to large-scale strategic deals.
  • Yuval Horn is, in our view, one of the standout lawyers in Israel’s high-tech sector. What makes him different is his ability to truly understand the mindset of founders and investors — he speaks the language of technology and business, not just law. Yuval has a rare talent for simplifying complex issues, anticipating risks before they arise, and guiding us toward solutions that are both practical and strategic. The team around him is equally impressive. The associates we have worked with are responsive, creative, and highly engaged, bringing real energy and insight to every matter. They understand the pace and pressures of the startup world and consistently deliver advice that is both technically precise and commercially relevant. For us, this combination of legal excellence, business acumen, and accessibility makes Gornitzky’s high-tech team a true partner in our growth.
  • ‘They understand the pace and pressures of the start-up world and consistently deliver advice that is both technically precise and commercially relevant.’
  • ‘What sets them apart is their ability to understand the realities of founders, investors, and fast-growing companies. They combine legal precision with a practical, business-minded approach, helping clients navigate everything from early-stage financings to large-scale strategic deals.’
  • ‘No other firm in Israel offers the same mix of hi-tech expertise, commercial insight, and client-focused service.’
  • ‘Yuval Horn is one of the standout lawyers in Israel.’
  • ‘What makes Yuval Horn different is his ability to understand the mindset of founders and investors - he speaks the language of technology and business, not just law.'
  • ‘Yuval Horn has a rare talent for simplifying complex issues, anticipating risks before they arise, and guiding clients toward solutions that are both practical and strategic.’
  • ‘The experience with the team is outstanding.’
  • ‘The team is very impressive. The associates are responsive, creative, and highly engaged, bringing real energy and insight to every matter.’

Key clients

  • V-Wave
  • Boston Scientific Corporation
  • TD Cowen
  • Guggenheim Securities
  • Ossio
  • Lutris Pharma
  • Aignostics
  • Theator
  • Scopio Labs
  • SurgiAI
  • E-Health Ventures
  • Pontifax Venture Capital Funds
  • MeMed Diagnostics
  • EdgeMed Ventures
  • MiCure Therapeutics
  • Kamari Pharma

Work highlights

Acted as Israeli counsel to V-Wave on its sale to Johnson & Johnson for a total consideration of US$1.675 billion.
Acted as Israeli counsel to Boston on its definitive agreement to acquire SoniVie, a privately-held, med-tech company.
Advised Lutris Pharma on a financing round of US$30 million, aimed at advancing the clinical development of LUT014.

Lawyers

Leading partners

The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.

Keren Kanir
Keren Kanir
Practice head

Yuval Horn

Other key lawyers

Shlomo Landress; Keren Kanir; Itamar Mei-Zahav; Oded Uni